A Matter of Preference

November 1, 2003

Amsterdam, The Netherlands - Methotrexate and cyclosporine do not differ significantly in efficacy as systemic therapies for moderate to severe chronic plaque psoriasis, according to Menno de Rie, M.D., Ph.D., associate professor of dermatology at the University of Amsterdam. Dr. de Rie and colleagues compared the two therapies in a randomized study of 88 patients with moderate to severe psoriasis.

Related Content:

News